June 2013 Newsletter
Inside Health Policy: “Safety, Generic Concerns Factors in Proposed AMA Biosimilar Resolution” A perceived lack of safety information about biosimilars and past problems with substitution of generic drugs led neurologists and rheumatologists to ask the American Medical Association to study the safety of follow-on biologics. AMA is expected to considerer the topic further at a […]